Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...

Gilead HPI licensing adds $35M now + $330M milestones; Phase 2 starts by 2026; strong cash runway. Click for this ASMB update ...

SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today ...

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ...

Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...

Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...

Assembly Biosciences (ASMB) announced interim results from two Phase 1b studies of its investigational long-acting herpes simplex virus helicase-primase inhibitors in participants seropositive for HSV ...

ASMB) on Thursday reported fourth-quarter net income of $22.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the South San Francisco, California-based company ...

SOUTH SAN FRANCISCO, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...